Scaling/Widening of AUC [Regulatives / Guidelines]

posted by Loky do – Egypt, 2021-02-24 14:13 (1548 d 10:18 ago) – Posting: # 22227
Views: 4,241

Dears
Also Regarding AUC widening, is it applicable in both partially and fully replicate designs or fully replicate design only as FDA referred to the published book chapter for RSABE for AUC and Cmax in fda draft guidance for progesterone? So could we apply it in general or it’s not applicable?

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,680 registered users;
54 visitors (0 registered, 54 guests [including 16 identified bots]).
Forum time: 01:32 CEST (Europe/Vienna)

Being really good at C++ is like being really good
at using rocks to sharpen sticks.    Thant Tessman

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5